Living Cell Technologies successfully treated its 1st patient in a clinical trial evaluating a new implantable regenerative therapy for treating Parkinson’s disease. The patient, the 1st enrolled in LCT’s Phase I clinical trial, was said to be recovering well in the days after the surgery.
The 1st patient was implanted with a new iteration of Medtronic’s deep brain stimulation device that delivers therapy while simultaneously recording brain activity.
The company is touting its Activa PC+S Deep Brain Stimulation system as a game-changer in the way neurological and psychological diseases are treated, thanks to its simultaneous treating and monitoring capabilities.
MASSDEVICE ON CALL —Senior officials at the Department of Veterans Affairs will see reduced salaries and fewer bonuses in 2014 after the House voted to send a message about the tomes of backlogged veteran’s disability claims.
The more than 800,000 backlogged veteran’s disability claims have been a hot-button issue across party lines, and the new budget beefs up allocated money for processing these claims while cutting down on senior official’s compensation.
Patients with Parkinson’s disease may benefit from receiving neurostimulating brain implants earlier in the course of the disease, according to researchers.
Treatment with neurostimulators, which delivery mild electrical pulses to targeted areas in the brain, are already standard for patients with advanced Parkinson’s disease, but researchers suggested that it may benefit patients "at an earlier stage than current recommendations suggest."
InSightec picked off $30.9 million in a Series C financing round, led by a $27.6 million investment from GE Healthcare and $3.3 million by other investors, the company said.
In addition, the Israeli-based ultrasound maker also named VP & general manager of the MRI business James Davis as new CEO and Tom Gentile as chairman of board. Gentile most recently was
president & CEO of GE Healthcare.